Drugs / tarenflurbil
tarenflurbil
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02206854 | Jun → Sep 2014 | — | Gerd Geisslinger | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00045123 | Feb 2002 → ? | prostate cancer | Myrexis Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00380276 | Sep 2006 → Dec 2008 | Alzheimer disease | Myrexis Inc. | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00322036 Comparator | May 2006 → Dec 2008 | Alzheimer disease | Myrexis Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00105547 Comparator | Feb 2005 → May 2008 | Alzheimer disease | Myrexis Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-12-12 | Mika Pharma GmbH | MIKA Pharma and GALENpharma report mutual development of tarenflurbil spray for dermatology mika-pharma.de ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tarenflurbil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00045123 ↗ |
| Known as | E-7869 | ChEMBL registry synonym — accepted as the source's own label CHEMBL190083 ↗ |
| Known as | MPC-7869 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00105547 ↗ |
| Known as | R-flurbiprofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02206854 ↗ |
| Known as | Tarenflurbilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL190083 ↗ |
| Modality | Small molecule | — CHEMBL190083 ↗ |
| Route | Oral | “oral 800 mg BID” NCT00105547 ↗ |